Novo Nordisk Shares Plunge 7% as Patent Expiry and Competition Concerns Mount
Novo Nordisk shares fell 7% after the company confirmed semaglutide patent expirations starting in 2032 and reported underwhelming Phase 3 trial results…
Novo Nordisk shares fell 7% after the company confirmed semaglutide patent expirations starting in 2032 and reported underwhelming Phase 3 trial results…
Critical Metals and Greenland Mines rally as a new U.S.-Denmark security pact sparks speculation of increased American investment in Greenland's rare earth…
Novo Nordisk shares dropped 6% following a capital markets day where the firm set long-term growth targets in line with industry peers,…
Ascendis Pharma reclaims full control of its TransCon metabolic pipeline from Novo Nordisk, trading partnership security for the potential to capture higher…
Novo Nordisk adopts the simplified 'Novo' brand identity as it pivots toward a more consumer-driven market strategy to regain its competitive edge…
Torm (TRMD) shares gain momentum as escalating U.S.-Iran tensions in the Strait of Hormuz push refined product shipping rates higher, bolstering the…
Revolut begins rolling out its EURR euro stablecoin to customers in Denmark, Poland and Portugal, a mainstream push that could accelerate euro…
Vestas shares surged 14% after the wind turbine manufacturer raised its full-year profit guidance and announced a share buyback, reflecting robust demand…
Denmark’s study on Wegovy’s employment effects puts Novo Nordisk’s obesity franchise under a policy spotlight with potential for expanded government backing.
Novo Nordisk’s blockbuster drug exports drive Denmark’s GDP growth above eurozone levels, per Danske Bank, fueling a trade surplus and potentially strengthening…
Novo Nordisk’s market dominance ties Denmark’s economic fate to its stock performance, with recent downturns casting a shadow over the nation’s growth…
BioMar's IPO, Denmark's biggest since 2018, saw shares rally on debut as investors bet on sustainable aquaculture growth.